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ABSTRACT
Adenylosuccinate synthetase (AdSS) is an enzyme at regulatory point of purine metabolism. In pathogenic
organisms which utilise only the purine salvage pathway, AdSS asserts itself as a promising drug target.
One of these organisms is Helicobacter pylori, a wide-spread human pathogen involved in the develop-
ment of many diseases. The rate of H. pylori antibiotic resistance is on the increase, making the quest for
new drugs against this pathogen more important than ever. In this context, we describe here the proper-
ties of H. pylori AdSS. This enzyme exists in a dimeric active form independently of the presence of its
ligands. Its narrow stability range and pH-neutral optimal working conditions reflect the bacterium’s high
level of adaptation to its living environment. Efficient inhibition of H. pylori AdSS with hadacidin and
adenylosuccinate gives hope of finding novel drugs that aim at eradicating this dangerous pathogen.
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Introduction
In order to effectively inhibit an enzyme, one should know its
properties and mechanism of action in the greatest possible
detail. If the enzyme in question (adenylosuccinate synthetase
(AdSS)) is a potential drug target against a wide-spread human
pathogen (Helicobacter pylori), the elaborate investigation of this
enzyme is all the more important.
AdSS (EC 6.3.4.4) catalyses the first step in the biosynthesis of
AMP from IMP, generating adenylosuccinate:
IMPþ Aspþ GTP Mg2þ
 
$ adenylosuccinateþ GDPþ Pi
In the second step, adenylosuccinate lyase cleaves adenylosucci-
nate to form AMP. AdSS operates at a branch point of the de novo
synthesis of purines and the purine nucleotide cycle, the so-called
salvage pathway, which makes this enzyme a challenging subject
to study1. AdSS activity has been observed in all the tissues investi-
gated, except in erythrocytes1. There are over 700 reviewed protein
entries for the gene name “purA” in the UniProt database (July
2018) from all domains of life. Two AdSS enzymes were identified
in vertebrates: acidic (pI 6) and basic (pI 9), presumably the for-
mer associated with the biosynthesis of purines and the latter with
the purine nucleotide cycle2. Regulation of activity of these two
isoforms is complex and different (as judged by different reactions
with inhibitors), and is dependent on the isozyme content and lev-
els in a given tissue, as well as substrate and product levels1. As
AdSS operates at a regulatory point in the metabolism of purines,
its substrate binding sites are quite specific3.
Bacterial AdSS enzymes resemble eukaryotic acidic isozymes in
their properties3. AdSS from Escherichia coli is probably the most
investigated of the kind. This protein exists in solution as a mix-
ture of monomers (47 kDa) and dimers (2 47 kDa), with
Kd¼ 10 mM for dimer dissociation4. In the presence of ligands
practically all of the protein is in the form of dimers4. As monomer
concentrations of AdSS are estimated to 1 mM in vivo, the enzyme
may be activated by substrate-induced dimerisation5. Initial-rate
kinetic studies by Rudolph and Fromm6 showed that the E. coli
AdSS kinetic mechanism is rapid-equilibrium random. This type of
mechanism was proven for several other AdSS enzymes1. The only
characterised AdSS differing so far is the one from Plasmodium
falciparum, reported to have ordered substrate binding7.
Numerous compounds have been investigated as potential inhib-
itors of E. coli AdSS, some of them listed in Supplementary Table S1.
Mostly product/feedback inhibition was studied (AMP8, adenylosucci-
nate6,8, GDP6,8, GMP8), as well as stringent response (guanosine 30,
50-bis(diphosphate) – ppGpp9, guanosine 50-diphosphate 20:30-cyclic
monophosphate – ppG20:30p10). Among other tested compounds,
some proved to be potent inhibitors, such as the herbicides hydan-
tocidin monophosphate3,11 and hadacidin11,12, and especially the
hybrid inhibitor obtained by linking these two molecules via a C3
methylene chain, which gave an IC50 of 0.043mM for E. coli AdSS
11.
Twenty-four 3D-structures of E. coli AdSS are deposited in Protein
Data Bank (PDB) (July 2018), and most of them comprise complexes
of the enzyme with the inhibitors mentioned above (usually in com-
bination with substrates). However, only a few structures of AdSS
from other microorganisms are available (unpublished, structures
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deposited in PDB) and the possible differences in active sites interac-
tions are yet unknown.
The bacterium H. pylori represents a serious threat to human
health. Even before its identification by Marshall and Warren13 it
was suspected as a causative agent of gastritis, ulcer, and gastric
cancer. Today it is proven to be involved in the development of
several diseases, such as chronic active gastritis, peptic ulceration,
gastric adenocarcinoma, and gastric mucosa-associated lymphoid
tissue lymphoma14. In 1994 it was classified as a class I human
carcinogen15. It is estimated that about half of the world’s popula-
tion is infected with this pathogen and its prevalence goes up to
80% in several countries, like Nigeria, Serbia, Nicaragua, and
Ecuador16, but also Latvia, Republic of Korea, and Japan (however,
mainly in older subjects)17. Standard triple therapy for H. pylori
infection consists of a proton pump inhibitor, amoxicillin, and cla-
rithromycin18. However, with growing resistance to antimicrobial
agents in H. pylori (up to 60% for clarithromycin in Korea19), new
antibiotics are included, like metronidazole, levofloxacin, sitafloxa-
cin, and rifabutin18. With a general increase in the consumption of
antibiotics, the number of resistant strains is also expected to rise,
so the search for novel targets for antimicrobial drugs is of utmost
importance.
When the genome of H. pylori was published20, it opened pos-
sibilities for studying the physiology of this pathogen in search of
promising drug targets21. It was observed that many of the redun-
dant metabolic pathways are missing, among them the de novo
synthesis of purines22. The fact that H. pylori relies exclusively on
the salvage pathway for the acquisition of purines, encouraged
studies of proteins involved in the purine salvage pathway (simi-
larly as in e.g. parasitic protozoa23). Liechti and Goldberg24 investi-
gated the growth of H. pylori mutants with deletions of purine
salvage pathway enzymes on media supplemented with various
purine nucleosides and bases and confirmed the essentiality of
this metabolic pathway. They found that the DpurA mutant (miss-
ing the gene purA encoding for AdSS) is capable of growth only
in a medium supplemented with adenine or adenosine and that
its growth was significantly retarded in nutrient-rich medium, thus
indicating the essentiality of AdSS for the salvage pathway24.
However, no records are available on the characterisation of this
enzyme, yet.
In our work, we have turned our attention to less investigated
enzymes from the purine salvage pathway of H. pylori, in hope of
identifying possible new drug targets for the eradication of this per-
sistent pathogen. Previously we described the catalytic properties and
3D-structure of purine nucleoside phosphorylase (PNP, EC 2.4.2.1)25,26
from this organism, and in this article we present the biochemical
and kinetic characterisation of H. pylori AdSS (UniProt ID: P56137),
along with its inhibition by a potent AdSS inhibitor, hadacidin, and
the reaction product, adenylosuccinate.
Materials and methods
Materials
Substrates for AdSS: L-aspartic acid monosodium salt monohy-
drate (Asp), inosine 50-monophosphate disodium salt hydrate
(IMP) and guanosine 50-triphosphate sodium salt hydrate (GTP)
were purchased from Sigma (St. Louis, MO). Inhibitors of AdSS:
hadacidin was purchased from Anji Biosciences (Hyderabad, India)
and adenylosuccinate from Santa Cruz Biotechnology Inc. (Dallas,
TX). Restriction enzymes and T4 DNA ligase used in DNA manipu-
lations were purchased from New England BioLabs (Ipswich, MA).
Media for bacterial growth was from Carl Roth (Karlsruhe,
Germany). Chromatography media and columns were produced
by GE Healthcare (Little Chalfont, UK). All other chemicals were
purchased from Sigma (if not stated otherwise) and were of the
highest available purity.
Cloning and sequencing of recombinant H. pylori AdSS
Genomic DNA of H. pylori strains ATCC 26695 was obtained from
the collection of the Department of Bacterial Genetics, Institute of
Microbiology, Faculty of Biology, University of Warsaw. The PCR
fragment corresponding to the H. pylori purA gene (gene coding
for AdSS protein, GenBank ID: AAD07324.1) was isolated from gen-
omic DNA and amplified using the Phusion High-Fidelity PCR kit
(New England BioLabs, Ipswich, MA) with a set of specific DNA pri-
mers for both the 5’ and the 3’ end of the gene. Both DNA pri-
mers contained additional flanking regions for introducing NdeI
and XhoI restriction sites at the purA gene’s 5’ and 3’ ends,
respectively. Primer NdeI-purA: 50-GCGTTGATCATATGGCAGATGTC
GTTGTGGG-30, primer XhoI-purA: 50-GGAGGATCTCGAGTCATAGAA
AAATCGTGTCTTCTCTTTCAGG-30. The reaction conditions for PCR
amplification were as follows: 30 s hot start at 98 C followed by
30 cycles of (1) denaturation at 98 C for 10 s, (2) annealing at
60 C for 30 s, and (3) elongation at 72 C for 1min. The final
elongation step was performed at 72 C for 10min. The purA gene
fragment (1.2 kb) obtained by PCR was purified from a 1% agar-
ose gel and ligated into the NdeI and XhoI restricted pET21b
expression vector (Invitrogen, Carlsbad, CA). The resulting plasmid,
pET21b-HPpurA, was transformed into E. coli strain XL-10 Gold
(Agilent Biotechnology, Santa Clara, CA) for multiplication. After
plasmid purification from the bacteria (using GenElute Plasmid
Miniprep Kit, Sigma-Aldrich, St. Louis, MO), the DNA sequence of
the H. pylori purA gene was confirmed by sequence analysis
(Macrogen Europe, Amsterdam, Netherlands).
Expression of recombinant H. pylori AdSS
pET21b-HPpurA was subcloned by electroporation into E. coli cell
strain BL21-CodonPlus(DE3)-RIL (Agilent Biotechnology, Santa
Clara, CA) which was used for expression of the recombinant
H. pylori AdSS. Enzyme expression was performed in the following
way. A 10mL sample of overnight E. coli culture was added to
500ml of LB medium (Carl Roth, Karlsruhe, Germany) containing
100mg/mL of ampicillin. The cells were grown at 37 C and
220 rpm to OD600¼ 0.6 and expression was induced with 0.5mM
IPTG (Isopropyl b-D-1-thiogalactopyranoside). The cells were add-
itionally grown for 4 h at 37 C and 220 rpm, and harvested at
5000g, at 4 C.
Purification of recombinant H. pylori AdSS
Purification was performed at þ4 C, in three chromatographic
steps, with a 10min centrifugation run at 10,000g and þ4 C
prior to loading the sample on each column.
Cells were lysed by incubation on ice for 30min with 1mg/mL
lysozyme in 50mM phosphate buffer pH 6.5 containing 2mM
EDTA (ethylenediaminetetraacetic acid), 0.1mM PMSF (phenylme-
thylsulfonyl fluoride) and 1mM DTT (dithiothreitol). This was fol-
lowed by cell sonication for 10 pulses of 30 s each, on ice. Finally,
DNaseI was added to the concentration of 3.6mg/mL and the sam-
ple incubated for 10min at room temperature (25 C) with shak-
ing. Cell debris was separated from protein extract by
centrifugation for 20min at 50,000g, at þ4 C. Any remaining
DNA in the protein extract was precipitated with 1% streptomycin
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sulphate and removed by centrifugation for 15min at 16,000g,
at þ4 C.
As a first step in the purification procedure, the protein extract
thus prepared was loaded onto cation-exchange chromatography.
SP-Sepharose FF was used (column dimensions 1.6 27.2 cm, i.e.
55mL) with a flow rate of 75mL/h and fractions of 5.0mL were
collected. The column was equilibrated in 50mM phosphate buf-
fer pH 6.5 containing 2mM EDTA and 1mM DTT. As it was
detected that AdSS was not bound to SP-Sepharose FF under
given conditions, all bound proteins were eluted with 1 M NaCl in
starting buffer.
Combined fractions containing AdSS were concentrated
through a PM-30 membrane (Merck, Darmstadt, Germany) in an
Amicon stirred cell and loaded onto a size-exclusion chromatog-
raphy (SEC) column (1.6 94.5 cm, i.e. 190mL) of Sephacryl
S-200HR (loaded sample volume equalled 1.5% of column
volume). Flow rate was maintained at 11mL/h and 2.3mL
fractions were collected. In this step 50mM phosphate buffer
pH 6.5 containing 150mM NaCl, 2mM EDTA and 1mM DTT
was used.
AdSS-containing fractions were pulled, concentrated through a
PM-30 membrane and transferred to 50mM Tris–HCl buffer pH 8.5
containing 1mM DTT (buffer A), by means of SEC on a PD-10 col-
umn (GE Healthcare). The sample thus prepared was loaded onto
the anion exchange chromatography column MonoQ 5/50 GL on
ÅKTA protein purification system (GE Healthcare). The column was
equilibrated in buffer A and elution was performed by gradually
increasing the concentration of NaCl (by mixing buffer A with buf-
fer B containing 1 M NaCl in buffer A): 0–30% B in 20mL and
30–100% B in 5mL. AdSS was found to elute at 85mM NaCl.
During this chromatography, flow rate was maintained at 60mL/h
and 1.0mL fractions were collected.
The final sample of AdSS for use in further experiments was
prepared by concentrating the enzyme through a 10 kDa MWCO
Hydrosart membrane in the Vivaspin2 device (Sartorius, G€ottingen,
Germany) and transferring it to 20mM HEPES-NaOH buffer
pH 6.5 containing 2mM TCEP (tris(2-carboxyethyl)phosphine
hydrochloride) by dialysis in the Tube-O-DIALYZER Micro device
(GBiosciences, St. Louis, MO).
The purification was monitored by electrophoresis under dena-
turing conditions (as described below) and a protein concentra-
tion assay following the method of Bradford27 with bovine serum
albumin as a standard.
SEC on a Sephacryl S-200HR column (under the conditions
described) was also used to estimate the molecular mass/oligo-
meric state of H. pylori AdSS. The column was calibrated
with several proteins from the Gel Filtration Calibration Kit
(GE Healthcare) – chymotrypsinogen A (25 kDa), bovine serum
albumin (67 kDa), aldolase (158 kDa), and catalase (232 kDa),
together with Blue Dextran. Ultraviolet absorption detection at
280 nm was used for determining the elution volume of the
marker proteins.
Electrophoresis under denaturing conditions
To follow the purification of H. pylori AdSS and to estimate the
final preparation purity and monomer molecular mass, horizontal
SDS-PAGE was performed on a PhastSystem apparatus (GE
Healthcare) following the manufacturer’s procedures. PhastGel
12.5% plates and SDS buffer strips were used, both from the same
producer, as well as the protein low molecular weight (LMW)
markers (14.4–93.0 kDa). Vertical SDS-PAGE was performed in a
Mini-PROTEAN Tetra Cell (Bio-Rad, Hercules, CA), according to the
manufacturer’s instructions. Gels (12.5%) for this system were
casted in-house, according to the manufacturer’s instructions.
LMW markers were also used in this system.
Prior to loading, samples were mixed with treatment buffer
(PhastSystem – 20mM Tris–HCl pH 8.0, 2mM EDTA, 5% SDS, 10%
2-mercaptoethanol; Mini-PROTEAN system – 0.125 M Tris–HCl
pH 6.8, 4% SDS, 20% glycerol, 2% 2-mercaptoethanol) in ratio 1:1
(v/v) and heated for 5min at 95 C. Gels were stained with
Coomassie Brilliant Blue R-250 (GE Healthcare) according to the
manufacturer’s instructions.
Enzyme activity assays
AdSS catalyses the reaction shown in the Introduction, utilising
three substrates: IMP, GTP, and Asp. The enzyme activity was
determined for the purified protein at pH 7.7, in 20mM HEPES-
NaOH buffer at 25 C. The reaction mixture contained 0.15mM
IMP, 5mM Asp, 0.06mM GTP and 1mM MgCl2 in the above-
mentioned buffer. The reaction course was monitored spectro-
photometrically by adding AdSS (approximately 1 mg) to 1mL of
the reaction mixture and by measuring the change in absorption
at 280 nm for three minutes. If nucleosides were omitted from the
reaction mixture (control for aspartase activity), the purified sam-
ple showed no change in absorbance. During purification, aspar-
tase activity interfered too much with the AdSS assay, and these
measurements are not exhibited in the results. The extinction
coefficient used to calculate the amount of the products formed
was 1.17 104 M1 cm1 (formation of adenylosuccinate)6.
One unit (U) of AdSS enzymatic activity is defined as mmol of
adenylosuccinate formed per min at 25 C. Specific activity is
expressed as units per mg of protein (U/mg).
Analytical ultracentrifugation
The oligomeric state of AdSS was studied by analytical centrifuga-
tion with absorbance and interference detection, and with the
sedimentation velocity method. Optima XL-I ultracentrifuge
(Beckman-Coulter Inc., Indianapolis, IN), An-50Ti and An-60Ti ana-
lytical rotors, and double-sector 1.2-cm cells with Epon-charcoal
centrepieces with sapphire or quartz windows were used. The par-
tial specific volume of H. pylori AdSS from its amino acid compos-
ition and densities and viscosities of buffers were calculated using
the Sednterp programme28.
Experiments were conducted at 50,000 rpm in 20mM HEPES-
NaOH pH 6.8þ 1mM TCEP, at 4 C or at 20 C and in 50mM
Tris–HCl þ2mM EDTA þ1mM DTT pH¼ 8.5 at 20 C (pH¼ 9.09 at
4 C). The protein samples (390mL) had a concentration in the
range 0.15–1.01mg/mL (3.3–22.1 mM of enzyme subunits). The
extinction coefficient E280nm¼ 38,850M1 cm1 according to
ProtParam29 was used to calculate the enzyme concentration.
The following ligands were used to get various binary, ternary,
and quaternary complexes of the enzyme: IMP (0.1mM and
3.0mM), GDP (5.0mM), GTP (4.0mM), hadacidin (1 and 5.5mM)
and MgSO4 (3.25mM). Presence of GDP and GTP in a concentra-
tion necessary to obtain complexes with AdSS causes the absorb-
ance to exceed the allowed limit. Therefore, interference detection
was used for all samples, while absorbance detection at 280 nm
was utilised only in three cases: for the apo enzyme, the binary
complex with 0.1mM IMP, and the ternary complex with 0.1mM
IMP and 1mM hadacidin.
Radial scans of the absorption and interference profiles in the
cell were measured at 5- or 7-min intervals on the same protein
samples. Analysis of the ultracentrifugation data was done by the
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Sedfit programme using the continuous c(S) distribution model
(www.analyticalultracentrifugation.com/)30. Both the sedimentation
coefficient s and the standard sedimentation coefficient s20,w were
calculated, and based on them the molecular mass of the species
present in the solution was determined, assuming that they have
the same friction ratio (also obtained as a parameter in the Sedfit
programme). Results shown in the text and in the Tables 1 and 2
are arithmetic means with standard error.
Temperature and pH effects on H. pylori AdSS stability
and activity
In all temperature and pH dependence studies, the AdSS activity
assay was used, as described above. The H. pylori AdSS concentra-
tion in all reaction mixtures was 1 mg/mL. All assays were done
in triplicate.
In experiments determining the effect of temperature on
enzyme activity, the reaction was performed at various tempera-
tures ranging from 25 to 70 C, after 5min of incubation of the
reaction mixture at a given temperature. The thermal stability of
H. pylori AdSS was determined by incubating the enzyme (0.1mg/
mL) in 20mM HEPES-NaOH buffer pH 7.7 for 1 h at various tem-
peratures in the range 25–50 C. And 10mL of the incubation mix-
ture was used for each activity measurement.
The reaction mixtures for testing the pH influence on the activ-
ity of H. pylori AdSS contained Britton–Robinson universal buffer
(BR buffer, a mixture of 40mM boric acid, 40mM phosphoric acid,
and 40mM acetic acid, titrated with 1 M NaOH)31 with pH in the
range from 5.0 to 9.0, instead of the HEPES-NaOH buffer pH 7.7.
The same molar extinction coefficient as above
(e¼ 1.17 104 M1 cm1) was used in the calculation of enzyme
activity, as the spectrum of adenylosuccinate was shown not to
change in this pH range32, which we also experimentally checked.
The effect of pH on H. pylori AdSS stability was tested by incubat-
ing the enzyme (0.1mg/mL) in BR buffer at different pH values
(5.0–9.5) for 1 h at 25 C. Then, 10mL of incubation mixture was
used for each activity measurement under standard conditions
(HEPES-NaOH buffer pH 7.7, 25 C).
Determination of kinetic constants
For the determination of kinetic constants, the concentration of
one substrate was varied at fixed saturating concentrations of the
other two substrates (0.06mM for GTP, 0.15mM for IMP and 5mM
for Asp). The concentration of GTP was varied between 0.6
and 120 mM, of IMP between 0.9 and 225 mM, and of Asp between
0.01 and 7.5mM. The data were analysed by fits of the
Michaelis–Menten equation (Equation (1)) using GraphPad Prism
version 7.03 (GraphPad Software, Inc., San Diego, CA).
V ¼ Vmax S½ = Km þ S½ ð Þ (1)
where V and Vmax are the initial velocity and maximum velocity,
respectively, Km is the Michaelis constant and [S] is the variable
substrate concentration.
In order to determine the Ki value of hadacidin, concentrations
of GTP and IMP were maintained at saturating levels (0.06 and
0.15mM, respectively), while initial concentrations of Asp and
hadacidin were varied from 0.01 to 1mM and from 0.3 to 4 mM,
respectively. On the other hand, in order to determine the Ki value
of adenylosuccinate, concentrations of GTP and Asp were
maintained at saturating levels (0.06 and 5mM, respectively),
while initial concentrations of IMP and adenylosuccinate were
Table 1. Distribution of Helicobacter pylori AdSS between dimeric and monomeric forms, sedimentation coefficients, and molecular masses of these forms, obtained
from the analytical ultracentrifugation studies of the apo enzyme, its binary complex with IMP and ternary complex with IMP and hadacidin.
Number of experiments Detection
Monomer Dimer
s0w,20 [S] MW
a [kDa] c(s) [%] s0w,20 [S] MW
a [kDa] c(s) [%]
pH 6.8, 4 C and 20 Cb
AdSS (4.4 or 14.9 mM) 4(7a) A280 nm 3.35–3.70 44.1 ± 1.8 2.0–16.9 5.27–5.82 88.0 ± 2.0 83.1–98.0
AdSS (5.1 mM) 1 Interference 3.73 61.1 8.7 5.70 115.5 91.3
AdSS (4.4 or 14.9 mM)
IMP (0.1mM)
3 A280 nm 3.10–3.82 42.8 ± 5.0 2.8–3.4 5.75–5.91 92.4 ± 3.8 96.6–97.2
AdSS (4.4 or 14.9 mM)
IMP (0.1mM)
Hadacidin (1mM)
3 A280 nm 2.70–3.53 35.0 ± 3.9 3.4–5.7 5.75–5.91 89.4 ± 0.7 94.3–96.6
pH 9.1, 4 Cc
AdSS (5.0 mM) 1 A280 nm 3.41 45.3 28.7 5.57 94.5 71.3
AdSS (13.4 mM) 1 A280 nm 3.54 49.0 28.0 5.45 93.8 72.0
AdSS (22.1 mM) 1 A280 nm 3.59 48.6 29.1 5.27 86.7 70.9
The sedimentation velocity method and absorbance at 280 nm and/or interference detection were used.
aTo determine MW of the apo enzyme results in TRIS–HCl pH 9.1, 4 C were also included.
bExperiments at 20mM HEPES-NaOH pH 6.8þ 1mM TCEP, enzyme activity 1.19 ± 0.10 U/mg.
cExperiments at 50mM TRIS–HCl pH 9.1 (at 4 C)þ 2mM EDTA þ1mM DTT, enzyme activity 0.75 U/mg.
Table 2. Distribution of AdSS between monomeric and dimeric forms observed in the analytical ultracentrifugation studies for various
enzyme complexes.
pH 6.8, 20 Ca
Monomer Dimer
c(s)b [%] c(s)b [%]
AdSSþGTPþ IMPþMgSO4 (5.1 mMþ 3.0mM þ3.0mM þ3.25mM) 10.2 89.8
AdSSþGDPþ IMP (5.1 mMþ 6.0mM þ3.0mM) 7.3 92.7
AdSSþGDPþ IMPþMgSO4 (5.1 mMþ 6.0mM þ3.0mM þ3.25mM) 14.9 85.1
AdSSþ IMP (5.1 mMþ 3.0mM) 11.3 88.7
AdSSþGDPþ IMPþMgSO4þHadacidin (5.1 mMþ 6.0mM þ3.0mM þ3.25mM þ5.5mM) 14.0 86.0
AdSSþGTPþ IMPþMgSO4þHadacidin (5.1 mMþ 3.0mM þ3.0mM þ3.25mM þ5.5mM) 14.4 85.6
The sedimentation velocity method with interference detection was used.
aExperiments at 20mM HEPES-NaOH pH 6.8þ 1mM TCEP, enzyme activity 1.02 U/mg.
bc(S) [%] under assumption that dimer and monomer are the only species present in the sample.
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varied from 7.5 to 225 mM and from 10 to 30mM, respectively. The
data were analysed by fits of the competitive inhibition model
(Equation (2)) using GraphPad Prism version 7.03.
V ¼ Vmax S½ = Km 1þ I½ =Ki
 þ S½   (2)
where V and Vmax are the initial velocity and maximum velocity,
respectively, Km is the Michaelis constant, Ki is the inhibition con-
stant and [S] is the variable substrate concentration.
Results and discussion
There are eight reviewed and over 400 un-reviewed AdSS protein
sequences from Helicobacter species in the UniProt database (July
2018). However, none has been studied in detail, yet.
Enzyme purification
AdSS from the pathogen H. pylori was purified using a three-step
procedure: cation exchange, size exclusion, and anion exchange
chromatography. The enzyme appeared homogeneous on SDS-
PAGE (Figure 1) and its molecular mass estimated from the SDS
gel (45.0 kDa) corresponds very well with the theoretical value (for
a monomer) of 45,742.72Da (as calculated by the ProtParam
tool29 on the ExPASy server). The molecular mass estimated from
SEC on the Sephacryl S-200HR column is 96.5 kDa (Supplementary
Figure S1), which indicates the existence of an enzyme dimer
under given conditions (see Materials and methods section).
According to the available literature, bacterial AdSS enzymes
are anionic and bind to anion exchangers, same as acidic mamma-
lian isozymes1. Most of them have a monomer molecular mass of
50 kDa and require dimerisation for achieving full enzymatic
activity1. The molecular mass of a H. pylori AdSS monomer fits
within the range of the so far characterised bacterial AdSS
enzymes. The elution volume from the SEC column indicates that
relatively high protein concentration (usually 15mg/mL of total
protein concentration in the sample loaded onto SEC) combined
with 0.15 M NaCl favour the presence of H. pylori AdSS dimers. A
shift towards monomers at higher ionic strength (200mM phos-
phate buffer) was observed for P. falciparum AdSS33, while a shift
towards dimers at higher protein concentrations and with the
presence of ligands was demonstrated for E. coli AdSS4.
The predicted pI for H. pylori AdSS (7.53, as calculated by the
ProtParam tool29 on the ExPASy server) is significantly higher than
the one predicted for other bacterial AdSS enzymes (7.53 com-
pared to 5–6 for AdSS from other bacteria). Binding to an anion
exchanger in the final purification step indicates the total protein
charge to be 7.5. Interestingly, the pI of H. pylori AdSS is very
similar to the pI of P. falciparum AdSS (pI 7.54). These parasitic
protozoa also lack the de novo purine synthesis pathway, and
similarly to H. pylori rely completely on the purine salvage path-
way for their purine nucleotide requirements33.
Determining the enzyme’s oligomeric state in the absence and
presence of ligands
Monomeric (inactive) and dimeric (active) forms of E. coli AdSS are
in dynamic equilibrium, and the enzyme exists solely in a dimeric
form either when the enzyme concentration is high (several mg/
mL) or when ligands are present. The Kd of a dimer falls from
10 mM in the absence of ligands to a value near zero in their pres-
ence4,34. To check if AdSS from H. pylori also shows such a behav-
iour, the oligomeric form of the apo enzyme, and its various
binary, ternary and quaternary complexes were studied by analyt-
ical centrifugation using the sedimentation velocity method.
At pH 6.8 where AdSS has the maximum of activity and stabil-
ity (Figure 3), ultracentrifugation experiments (Figure 2), con-
ducted for 0.2mg/mL (4.4mM) and 0.68mg/mL (14.9 mM) AdSS, at
4 C and at 20 C, with absorption detection at 280 nm, show that
the majority of the sample (from 83.1 to 98.0%, see Table 1) con-
stitutes a species with a sedimentation coefficient s020,w in the
range 5.70–5.82 S and molecular mass MW ¼ 88.0 ± 2.0 kDa, hence
corresponding to a dimer (the theoretical mass of the monomer
from its sequence is 45,742.72Da). The rest of the protein is in the
monomeric form with MW ¼ 44.1 ± 1.8 kDa. However, a very simi-
lar amount of the monomer (see Table 1) is observed also in the
presence of ligands, 0.1mM IMP alone and with addition of 1mM
hadacidin (competitive inhibitor of aspartic acid, see
Supplementary Table S1 and section below). This suggests that, in
contrast to E. coli AdSS4,35, monomer and dimer of the H. pylori
counterpart may not be in a dynamic equilibrium and binding of
ligands by this enzyme may not push the equilibrium towards
the dimer.
The presence of a higher concentration of IMP, as well as GTP
or GDP, results in absorption exceeding the allowed limit, there-
fore the following experiments were done with interference detec-
tion only, which enables the use of high concentrations of all
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Figure 1. (A) SDS-PAGE of purified H. pylori AdSS, lane 1 – pulled fractions after SEC on Sephacryl S-200HR, lane 2 – LMW protein markers (molecular masses in kDa
given in the figure), lanes 3 & 4 – purified AdSS. (B) Calibration curve for the given gel, Rf is ratio of migration distance of the protein and migration distance of the
dye front.
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ligands, including those absorbing in the near UV region.
Comparison of both detection methods for the apo enzyme (see
Figure 2(B) and Table 1) shows that they both give similar results
regarding the monomer/dimer ratio, thus justifying the use of the
interference detection method to determine the distribution of
AdSS complexes between dimeric and monomeric forms.
Interference detection experiments were therefore conducted
for various binary, ternary and quaternary AdSS complexes and
the results obtained are shown in Figure 2(C) and Table 2. These
data indicate that none of the ligand combinations used in these
studies, despite the high ligand concentrations utilised, were able
to increase significantly the amount of dimers relative to mono-
mers. Hence this proves that H. pylori AdSS is a dimer even at
concentrations as low as several mM, regardless of the presence of
ligands, and that the enzyme subunits indeed are not in a
dynamic equilibrium. The data also suggest that the monomer
observed in the experiments is most probably an irreversible inter-
mediate on the inactivation pathway of the enzyme. This is further
supported by the results of the next experiment, conducted at pH
9.1 (Table 1), hence under conditions where the enzyme is less
stable (see Figure 3), which showed an increased amount of the
monomeric form (28.0–29.1%), regardless the enzyme concentra-
tion of the sample used.
These data suggest that the AdSS form of H. pylori is a dimer
in vivo and its activity is not regulated, like that of the E. coli
enzyme, by a substrate-induced dimerisation. This seems to be in
line with the fact that the de novo purine synthesis pathway is
missing in H. pylori and the purine salvage pathway is the only
source of purines for this organism22. It seems likely that the
enzymes of this pathway are constantly active to meet the purine
nucleotide demands of the organism.
Effect of pH and temperature on enzyme activity and stability
Purified H. pylori AdSS was most active under chosen conditions
(see Materials and methods section) at pH 7.0 and 50 C (Figure 3).
The enzyme was stable (retaining 90% of the initial activity) in
the pH range 6.5–8.5 at 25 C and up to 37 C at pH 7.0 (Figure 3).
Purified AdSS retained its full activity for 11 days when incu-
bated at 25 C at a concentration of 0.57mg/mL, and lost no activ-
ity through several cycles of freezing (80 C) and thawing.
There is a surprisingly low amount of data on AdSS proteins
regarding their stability and optimal catalysis conditions. In the
review by Stayton et al.1 only a note on pH optimum can be
found, stating that AdSS enzymes from various sources have pH
optima in the pH range 6.5–7.5. Additionally, we were able to find
data for AdSS from P. falciparum – pH optimum in the pH range
6.8–7.533. AdSS from yeast Saccharomyces cerevisiae was better
characterised – optimal activity at 35 C and pH ¼ 7.0, enzyme
stable in the wide pH range 5–10 and up to 37 C36. Temperature
optimum is known to be the result of two processes – rise in
enzyme activity and protein denaturation with rising tempera-
ture37. With that in mind, the temperature optimum of H. pylori
AdSS of 50 C in comparison with its low temperature stability can
be explained by the short time of enzymatic activity measure-
ment (3min).
H. pylori has been evolving alongside humans for hundreds of
thousands of years and thus became very well adapted to condi-
tions in the human stomach24. Its metabolism is optimised for liv-
ing in the acid environment of the stomach and for using
available nutrients for growth22. For example, a characteristic fea-
ture of H. pylori is the generation of the enzyme urease that catal-
yses decomposition of urea. As one of the products is ammonia,
this reaction results in an increase of pH in the immediate
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Figure 2. The absorption at 280 nm, A280nm(s), and the interference(s) profiles obtained from fitting the continuous c(s) distribution model to the sedimentation vel-
ocity data acquired for Helicobacter pylori AdSS at 20mM HEPES-NaOH pH 6.8þ 1mM TCEP, at 20 C. (A) A280 nm(s) profile for the 4.4 mM of the apo AdSS (black);
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environment. This is one of the key factors of survival of H. pylori
in an unfavourable environment14,20,38. In this context, it is under-
standable that the pH optimum of H. pylori AdSS is in the neutral
pH range and that the enzyme is stable and active at physio-
logical temperatures maintained within the human body, the host
of this pathogen.
Kinetic characterisation of the enzymatic reaction
Kinetic constants determined for all three substrates of AdSS, IMP,
GTP, and Asp are given in Table 3. For each substrate, the curve
of initial velocity over substrate concentration follows
Michaelis–Menten kinetics (Equation (1)). When comparing
Michaelis constants of H. pylori AdSS with those of other organ-
isms, it can be observed that they are similar to those of e.g.
E. coli AdSS (GTP: 10–48mM, IMP: 20–200 mM, and Asp:
260–350mM) or mouse basic isozyme (GTP: 12 mM, IMP: 45mM,
and Asp: 140 mM), while e.g. the mouse acidic isozyme (GTP:
15mM, IMP: 12mM, and Asp: 950 mM) or P. falciparum AdSS (GTP:
18mM, IMP: 23mM, and Asp: 1800mM) have significantly higher
values of Km for Asp
1,39. Turnover number (kcat) of 1 s
1 compares
well with kcat for E. coli and P. falciparum AdSS enzymes, however,
both mouse enzymes have 4- to 5-fold higher efficacy39. This low
value of kcat makes AdSS one of the least efficient enzymes
described in the literature, and for E. coli the AdSS reaction is near
the rate-limiting step in the bacterium’s growth and reproduction
cycle3. This is in line with the known fact that purine metabolism
is the growth-limiting step for all cells, both prokaryotic and
eukaryotic24.
Enzyme inhibition with hadacidin
Hadacidin is a natural antibiotic, the fermentation product of
Penicillium frequentans40. It has been shown to diminish AdSS
activity as a competitive inhibitor of aspartic acid3. The inhibition
constant (Ki) for its activity on H. pylori AdSS was determined to
be 0.19 ± 0.02 mM. The competitive effect of hadacidin on AdSS
activity was confirmed by plots of initial velocity over substrate
concentration and Dixon plots (1/v vs. inhibitor concentration), as
shown in Figure 4.
The hadacidin inhibition constant of H. pylori AdSS is the low-
est known so far. Those reported for other enzymes span from
0.3 mM for AdSS from Aztobacter vinelandii41 to 10.5mM for the
same enzyme from the thermophilic archaeon
Methanocaldococcus jannaschii39. For E. coli AdSS values from 1.0
to 4.2mM were reported42,43, and for P. falciparum 5.6mM7.
Attempts have been made to improve hadacidin inhibition of
AdSS by creating its analogous, with no significant results44,45.
Enzyme inhibition with adenylosuccinate
Adenylosuccinate is the product of the AdSS reaction (see
Introduction). The inhibition constant (Ki) for its activity on H. pylori
AdSS was determined to be 3.5 ± 0.3mM. The competitive effect of
adenylosuccinate on AdSS activity (towards IMP) was confirmed by
plots of initial velocity over substrate concentration and Dixon
plots (1/v vs. inhibitor concentration), as shown in Figure 5.
AdSS enzymes were shown to be susceptible to product and
feedback inhibition. Adenylosuccinate is a strong inhibitor with Ki
in the range 5–30mM for bacterial enzymes1. For the E. coli
enzyme it was shown that adenylosuccinate inhibits AdSS
competitively with respect to IMP with a Ki of 5 mM
6. The same
behaviour was observed for AdSS enzymes from A.
vinelandii (Ki¼ 2.5 mM)41, M. jannaschii (Ki¼ 9.4mM)39 and P.
falciparum (Ki¼ 29 mM)7.
Conclusions
This article represents the very first description of the biochemical
and kinetic properties of AdSS from the bacterium H. pylori.
Although similar to other characterised bacterial AdSS enzymes
(represented by E. coli AdSS, protein sequence identity with H.
pylori AdSS: 43.7%, as calculated by ClustalO46 on ExPASy server)
in size and kinetic properties, H. pylori AdSS also shares attributes
(like isoelectric point and oligomeric state) with AdSSs from proto-
zoan parasites (like P. falciparum) which also lack the de novo pur-
ine synthesis pathway. Strong inhibition of H. pylori AdSS with
hadacidin and adenylosuccinate provides foundation for further
work on finding novel inhibiting compounds and solving the 3D-
structure of this enzyme in its apo form and in various complexes,
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Figure 3. Effect of A) pH, and B) temperature on H. pylori AdSS stability (––) and activity (––). The exact conditions are described in Materials and meth-
ods section.
Table 3. Kinetic parameters for H. pylori AdSS, obtained by fitting the
Michaelis–Menten equation to the experimental data. Fitting errors of the kinetic
parameters obtained are shown in the table.
Variable
substrate
Fixed substrates’
concentration (mM) Km (mM) Vmax (U/mg)
GTP IMP – 0.15, Asp – 5.0 8.7 ± 0.6 1.418 ± 0.023
IMP GTP – 0.06, Asp – 5.0 40.1 ± 2.9 1.456 ± 0.036
Asp GTP – 0.06, IMP – 0.15 125.4 ± 7.7 1.103 ± 0.016
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which is something we are currently working on. The results pre-
sented here on H. pylori AdSS, along with future findings, give
hope of finding novel antibiotics against this danger-
ous pathogen.
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